RESUMO
Primary biliary cholangitis is a cholestatic, chronic autoimmune liver disease with a wide individual variation in disease progression. The diagnosis is predominantly based on chronic elevation of alkaline phosphatase and the presence of anti-mitochondrial antibodies or other specific antinuclear antibodies (i.e. anti-gp210 and anti-sp100). Even in early-stage disease, health-related quality of life can be severely impaired by symptoms such as pruritus, fatigue, and sicca syndrome and metabolic bone disease should be assessed and treated. The prognosis of the disease is, however, largely determined by the development of cirrhosis and its complications. Ursodeoxycholic acid is associated with an improved prognosis and should be initiated and continued in all patients. Clinical outcome is related to the biochemical response to ursodeoxycholic acid, but the prognosis of those with an incomplete response is still better than those who remain untreated. Obeticholic acid was recently approved as second-line treatment and bezafibrate may serve as an adequate off-label alternative, particularly in patients with pruritus. Preliminary data suggest an additive effect of triple therapy with ursodeoxycholic acid, obeticholic acid, and bezafibrate, whereas other promising drugs are being evaluated in clinical trials.
Assuntos
Doenças Autoimunes/diagnóstico , Colagogos e Coleréticos/uso terapêutico , Doença Hepática Terminal/terapia , Cirrose Hepática Biliar/diagnóstico , Transplante de Fígado , Autoantígenos/imunologia , Doenças Autoimunes/imunologia , Doenças Autoimunes/mortalidade , Doenças Autoimunes/terapia , Bezafibrato/uso terapêutico , Biomarcadores/sangue , Biomarcadores/metabolismo , Biópsia , Ácido Quenodesoxicólico/análogos & derivados , Ácido Quenodesoxicólico/uso terapêutico , Progressão da Doença , Quimioterapia Combinada/métodos , Técnicas de Imagem por Elasticidade , Doença Hepática Terminal/diagnóstico , Doença Hepática Terminal/imunologia , Doença Hepática Terminal/mortalidade , Fadiga/diagnóstico , Fadiga/imunologia , Fadiga/terapia , Feminino , Humanos , Imunoglobulina M/sangue , Imunoglobulina M/imunologia , Fígado/diagnóstico por imagem , Fígado/enzimologia , Fígado/imunologia , Fígado/patologia , Cirrose Hepática Biliar/imunologia , Cirrose Hepática Biliar/mortalidade , Cirrose Hepática Biliar/terapia , Testes de Função Hepática , Pessoa de Meia-Idade , Uso Off-Label , Prognóstico , Prurido/diagnóstico , Prurido/imunologia , Prurido/terapia , Qualidade de Vida , Índice de Gravidade de Doença , Síndrome de Sjogren/diagnóstico , Síndrome de Sjogren/imunologia , Síndrome de Sjogren/terapia , Taxa de Sobrevida , Resultado do Tratamento , Ácido Ursodesoxicólico/uso terapêuticoRESUMO
BACKGROUND: Primary biliary cholangitis (PBC) is an autoimmune hepatobiliary disorder characterized by destruction of liver bile ducts leading to intrahepatic cholestasis. It causes intractable pruritus for which ultraviolet (UV)B phototherapy is an experimental treatment when alternative therapies fail. The pathophysiology of cholestatic itch and the mechanism of action of narrowband UVB in this condition remains poorly understood. OBJECTIVES: To summarize the current literature and propose testable hypotheses for the mechanism of action of phototherapy in attenuating itch. METHODS: A focused PubMed search for articles relating to the pathogenesis of itch in cholestatic disease was performed. A total of 3855 articles were screened and 50 were found suitable for literature review. Evidence from this literature review was combined with author expertise in the area. RESULTS: Formulated hypotheses focus on the role of bile salts, autotaxin and specific receptors including G-protein-coupled bile acid receptor, Gpbar1 (also known as TGR5) and the nuclear transcription factor farnesoid X receptor. CONCLUSIONS: Several testable mechanisms through which phototherapy may exert its effects are discussed in this review. The next steps are to carry out an objective assessment of the efficacy of phototherapy in cholestatic pruritus, gain further knowledge on the underlying pathways, and subsequently trial its use against current licensed therapies. Such studies could lead to increased mechanistic understanding, identification of novel therapeutic targets and the potential to refine phototherapy protocols, leading to improved control of itch and quality of life in patients with PBC. What's already known about this topic? Primary biliary cholangitis (PBC) is frequently associated with intractable pruritus for which current treatment options are often unsuccessful. Phototherapy is used as an experimental treatment for PBC-associated pruritus when alternative better-studied treatments fail. What does this study add? This study reviews the current literature on the pathophysiology and management of cholestatic pruritus, an area which remains poorly understood. We propose testable hypotheses of the mechanisms behind the attenuation of cholestatic pruritus with phototherapy.
Assuntos
Cirrose Hepática Biliar/complicações , Prurido/imunologia , Pele/imunologia , Terapias em Estudo/métodos , Terapia Ultravioleta/métodos , Ácidos e Sais Biliares/imunologia , Ácidos e Sais Biliares/metabolismo , Ácidos e Sais Biliares/efeitos da radiação , Humanos , Cirrose Hepática Biliar/sangue , Cirrose Hepática Biliar/imunologia , Lisofosfolipídeos/imunologia , Lisofosfolipídeos/metabolismo , Diester Fosfórico Hidrolases/metabolismo , Prurido/sangue , Prurido/patologia , Prurido/radioterapia , Receptor PAR-2/metabolismo , Eliminação Renal/efeitos da radiação , Transdução de Sinais/efeitos dos fármacos , Pele/patologia , Pele/efeitos da radiação , Resultado do Tratamento , Triptases/metabolismoRESUMO
RATIONALE: Primary biliary cholangitis (PBC) is a liver autoimmune disease. If this disease is associated with other liver injury factors, both misdiagnosis and missed diagnosis will easily occur. Therefore, detailed disease history collection and related laboratory examination should be performed on patients with liver injury for unidentified causes. When necessary, liver biopsy should be performed to confirm the histopathological diagnosis. PATIENT CONCERNS: The subject patient was a 63-year-old Chinese male with chronic liver injury who had a drinking history of about 30 years and drank 500âg daily on average and began to take health products and dietary supplements (multivitamins) since June 2014. DIAGNOSES: Drug-induced liver injury (DILI) and alcoholic fatty liver disease (AFLD) were initially considered because the patient had a history of using health products (HP) and dietary supplements (DS) and drinking alcohol. However, he was subsequently considered with PBC based on the findings of anti-mitochondrial antibody positivity and elevated immunoglobulin level. Obstructive jaundice and space-occupying lesion in the liver were excluded by imaging examinations. Liver biopsy was performed to confirm the reasons for liver injury. Histopathological examination was conducted, and the patient was diagnosed with PBC associated with DILI and alcoholic liver fibrosis. INTERVENTIONS: Ursodeoxycholic acid, glycyrrhizic acid, and methylprednisolone (small dose) were used to treat the patient. OUTCOMES: After 2 months, the serum levels of ALT, AST, AKP, GGT, and globulin returned to normal. After 4 months, the patient showed liver injury once again (an increase in ALT, AST, AKP, GGT and GLB) caused by repaglinide administration due to hyperglycemia. Ursodeoxycholic acid and methylprednisolone replaced the repaglinide administration. After 3 weeks, the levels of ALT, AST, AKP, GGT, and GLB returned to normal again. LESSONS: The correct knowledge on PBC and early-stage recognition and diagnosis should be emphasized. When other causes of the liver injury cannot be excluded, liver biopsy is suggested. Histopathological change can be used to further clarify the reasons for liver injury and the principal contradiction as well as to guide the theraputic regimen.
Assuntos
Doença Hepática Induzida por Substâncias e Drogas/complicações , Colangite/etiologia , Fígado Gorduroso Alcoólico/complicações , Cirrose Hepática Biliar/etiologia , Colangite/imunologia , Humanos , Cirrose Hepática Biliar/imunologia , Masculino , Pessoa de Meia-IdadeAssuntos
Doenças Autoimunes/diagnóstico , Dermatite/diagnóstico , Cirrose Hepática Biliar/complicações , Idoso , Autoanticorpos/sangue , Autoanticorpos/imunologia , Doenças Autoimunes/sangue , Doenças Autoimunes/etiologia , Doenças Autoimunes/patologia , Biópsia , Colagogos e Coleréticos/uso terapêutico , Dermatite/sangue , Dermatite/etiologia , Dermatite/patologia , Medicamentos de Ervas Chinesas/uso terapêutico , Antebraço , Humanos , Cirrose Hepática Biliar/diagnóstico , Cirrose Hepática Biliar/tratamento farmacológico , Cirrose Hepática Biliar/imunologia , Masculino , Mitocôndrias/imunologia , Pele/imunologia , Pele/patologia , Resultado do Tratamento , Ácido Ursodesoxicólico/uso terapêuticoRESUMO
There remain significant obstacles in developing biologics to treat primary biliary cholangitis (PBC). Although a number of agents have been studied both in murine models and human patients, the results have been relatively disappointing. IL-22 is a member of the IL-10 family and has multiple theoretical reasons for predicting successful usage in PBC. We have taken advantage of an IL-22 expressing adeno-associated virus (AAV-IL-22) to address the potential role of IL-22 in not only protecting mice from autoimmune cholangitis, but also in treating animals with established portal inflammation. Using our established mouse model of 2-OA-OVA immunization, including α-galactosylceramide (α-GalCer) stimulation, we treated mice both before and after the onset of clinical disease with AAV-IL-22. Firstly, AAV-IL-22 treatment given prior to 2-OA-OVA and α-GalCer exposure, i.e. before the onset of disease, significantly reduces the portal inflammatory response, production of Th1 cytokines and appearance of liver fibrosis. It also reduced the liver lymphotropic chemokines CCL5, CCL19, CXCL9, and CXCL10. Secondly, and more importantly, therapeutic use of AAV-IL-22, administered after the onset of disease, achieved a greater hurdle and significantly improved portal pathology. Further the improvements in inflammation were negatively correlated with levels of CCL5 and CXCL10 and positively correlated with levels of IL-22. In conclusion, we submit that the clinical use of IL-22 has a potential role in modulating the inflammatory portal process in patients with PBC.
Assuntos
Doenças Autoimunes/terapia , Terapia Biológica/métodos , Colangite/terapia , Interleucinas/imunologia , Fígado/imunologia , Sistema Porta/imunologia , Animais , Quimiocina CCL19/imunologia , Quimiocina CCL19/metabolismo , Quimiocina CCL5/imunologia , Quimiocina CCL5/metabolismo , Quimiocina CXCL10/imunologia , Quimiocina CXCL10/metabolismo , Quimiocina CXCL9/imunologia , Quimiocina CXCL9/metabolismo , Dependovirus , Modelos Animais de Doenças , Feminino , Galactosilceramidas/imunologia , Galactosilceramidas/farmacologia , Vetores Genéticos , Interleucinas/genética , Fígado/irrigação sanguínea , Cirrose Hepática Biliar/imunologia , Cirrose Hepática Biliar/terapia , Camundongos , Camundongos Endogâmicos C57BL , Sistema Porta/patologia , Interleucina 22RESUMO
Despite the presumed immunological pathogenesis of primary biliary cirrhosis, no clear or even harmful consequences resulted from some specific treatments addressed to modify the immunological condition. However, ursodeoxycholic acid (UDCA; 13-16 mg/kg/d) has clear favorable effects not only by improving biochemical cholestasis, but also by delaying the histological progression. Long -term treatment with UDCA is associated with excellent survival, free of transplantation in cases showing biochemical response at one year. In the remaining patients, data on the effect of fibrates, budesonide, or obeticholic acid are encouraging. Pruritus is usually managed using resins; further steps are needed in resistant cases with the use of rifampicin, naltrexone, sertraline, or invasive procedures such as albumin dialysis. Osteoporosis, which is highly prevalent in patients with deep and prolonged cholestasis, improves with bisphosphonates; current data indicate that both weekly alendronate and monthly ibandronate increase bone mass in patients with osteoporosis. Nutritional and fat-vitamin supplementation is also mandatory in patients with severe cholestasis.
Assuntos
Ductos Biliares Intra-Hepáticos/efeitos dos fármacos , Fármacos Gastrointestinais/uso terapêutico , Cirrose Hepática Biliar/tratamento farmacológico , Anti-Inflamatórios/uso terapêutico , Antipruriginosos/uso terapêutico , Ductos Biliares Intra-Hepáticos/imunologia , Ductos Biliares Intra-Hepáticos/patologia , Conservadores da Densidade Óssea/uso terapêutico , Colagogos e Coleréticos/uso terapêutico , Suplementos Nutricionais , Quimioterapia Combinada , Fármacos Gastrointestinais/efeitos adversos , Humanos , Cirrose Hepática Biliar/complicações , Cirrose Hepática Biliar/diagnóstico , Cirrose Hepática Biliar/imunologia , Transplante de Fígado , Osteoporose/tratamento farmacológico , Osteoporose/etiologia , Prurido/tratamento farmacológico , Prurido/etiologia , Resultado do Tratamento , Ácido Ursodesoxicólico/uso terapêuticoRESUMO
Primary biliary cirrhosis (PBC) is characterized by chronic destructive cholangitis, which is associated with the reduced expression of an anti-inflammatory molecule, peroxisome proliferator-activated receptor-γ (PPARγ), in intrahepatic bile ducts. We previously demonstrated the anti-inflammatory effects of PPARγ ligands using cultured human biliary epithelial cells. In this study, we evaluated the effectiveness of PPARγ ligand against peribiliary inflammation in vivo. As an animal model of PBC, we used MRL/lpr mice in which a PBC-like cholangitis occurs naturally. Anti-inflammatory effects of the intraperitoneal administration of a PPARγ ligand, the prostaglandin D metabolite 15-deoxy-Δ(12,14)-prostaglandin J2 (15d-PGJ2), were evaluated. In untreated mice, portal inflammation including cholangitis was found to some degree in the majority of portal tracts. In mice given a high-dose group, the degree of portal inflammation was significantly reduced and mice mostly lacking portal inflammation and cholangitis were also found. T cell numbers in portal tracts were markedly decreased in the high-dose group, compared with controls, whereas there was no significant difference in terms of B cells and macrophages. This study is the first to assess the therapeutic potential of a PPARγ ligand against portal inflammation including cholangitis. Anti-inflammatory effects of PPARγ ligands may prevent the progression of cholangiopathy in PBC patients.
Assuntos
Colangite/tratamento farmacológico , Cirrose Hepática Biliar/tratamento farmacológico , PPAR gama/agonistas , Sistema Porta/imunologia , Prostaglandina D2/análogos & derivados , Animais , Colangite/imunologia , Avaliação Pré-Clínica de Medicamentos , Feminino , Humanos , Circulação Hepática , Cirrose Hepática Biliar/imunologia , Masculino , Camundongos , Camundongos Transgênicos , PPAR gama/metabolismo , Sistema Porta/efeitos dos fármacos , Prostaglandina D2/administração & dosagemRESUMO
OBJECTIVE: To observe the efficacy of ursodeoxycholic acid (UDCA) combined with Tongdan: Decoction () on immunological indices and histopathological changes in patients with primary biliary cirrhosis (PBC) of IIor III histological stage. METHODS: Sixty PBC patients were assigned randomly and equally: to the control group treated with UDCA alone and the treatment group treated with UDCA combined with Tongdan Decoction. The immunological indices and histopathological changes were detected before and after 24-week treatment, and the follow-up lasted for 1-3 years. RESULTS: After 24-week treatment, CD4(+)CD28(-) in the peripheral blood was lowered and CD4(+)CD25(+) was increased in both groups, and better effect was shown in the treatment group (P<0.01). The levels of IgM, IgG, and IgA decreased markedly after 96-week treatment in the treatment group (P< 0.05, P< 0.01), while in the control group, only the latter two showed significant decrease after 148 week (all P<0.05). At the end of the 3-year follow-up, the medians of histopathological Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico
, Cirrose Hepática Biliar/tratamento farmacológico
, Cirrose Hepática Biliar/patologia
, Ácido Ursodesoxicólico/uso terapêutico
, Antígenos CD/sangue
, Biomarcadores
, Quimioterapia Combinada
, Feminino
, Humanos
, Imunoglobulina G/sangue
, Inflamação/sangue
, Inflamação/complicações
, Cirrose Hepática Biliar/sangue
, Cirrose Hepática Biliar/imunologia
, Masculino
, Pessoa de Meia-Idade
RESUMO
BACKGROUND: An inflammatory immune system response ensues in the liver and in the systemic circulation in cirrhosis, where it contributes to hepatic fibrosis and peripheral vasodilation. Modulation of the inflammatory response without increasing susceptibility to infection is a therapeutic target in cirrhosis. AM3 is a low-toxicity biological response modifier with regulatory effects on innate and adaptative immunity, and the ability to normalise the production of tumour necrosis factor alpha (TNFalpha). AIMS: This was an experimental study to investigate the effects of oral AM3 on the systemic and hepatic inflammatory response, liver fibrosis and on the haemodynamic abnormalities of portal hypertension in rats with biliary cirrhosis. DESIGN: Bile-duct ligated rats received a 3-week oral course of AM3 or placebo. RESULTS: In cirrhotic rats, AM3 blunted the inflammatory switch of circulating and intrahepatic monocytes and T-cells to TNFalpha and interferon gamma (IFNgamma) production, respectively. AM3 modified the intrahepatic polarisation pattern of the regulatory cytokines, decreasing the mRNA expression of transforming growth factor beta1 (TGFbeta1), interleukin 4 (IL4), and IFNgamma, and increasing that of IL10. Total and IFNgamma-producing natural killer (NK) cells were lowered by AM3 in the peripheral blood and liver of cirrhotic rats. The immunomodulatory effects of AM3 led to reduced hepatic fibrogenesis in cirrhotic rats, as shown by decreased area of liver fibrosis, hydroxyproline content and mRNA expression of procollagen alpha1(I). Besides, AM3 lowered portal pressure and systemic hyperaemia. CONCLUSIONS: The biological response modifier AM3 reverses the concurrent inflammatory immune system activation in peripheral blood and liver of experimental established cirrhosis, which results in reductions of hepatic fibrosis, portal pressure and peripheral vasodilation.
Assuntos
Adjuvantes Imunológicos/uso terapêutico , Fosfatos de Cálcio/uso terapêutico , Glicopeptídeos/uso terapêutico , Cirrose Hepática Biliar/tratamento farmacológico , Cirrose Hepática Experimental/tratamento farmacológico , Animais , Citocinas/sangue , Avaliação Pré-Clínica de Medicamentos/métodos , Imunomodulação , Imunofenotipagem , Células Matadoras Naturais/efeitos dos fármacos , Células Matadoras Naturais/imunologia , Fígado/imunologia , Cirrose Hepática Biliar/imunologia , Cirrose Hepática Biliar/patologia , Cirrose Hepática Experimental/imunologia , Cirrose Hepática Experimental/patologia , Masculino , Monócitos/efeitos dos fármacos , Monócitos/imunologia , Ratos , Ratos Wistar , Subpopulações de Linfócitos T/efeitos dos fármacos , Subpopulações de Linfócitos T/imunologiaRESUMO
Delayed in vivo elimination of autologous erythrocytes coated with immunoglobulin G has been reported in autoimmune and inflammatory gastrointestinal diseases. Our aim was to elucidate whether impairment of the macrophages was restricted to the Fc receptors of the reticuloendothelial system or whether complement receptors were also affected. We studied elimination by complement receptors of autologous erythrocytes coated with fragments of C3 and C4 in patients with primary biliary cirrhosis, ulcerative colitis, and alcoholic cirrhosis. Impaired function was seen in all patient groups as compared with function in normal subjects, both concerning the mean half-life of the injected cells and the total number of eliminated erythrocytes. Neither of these parameters correlated with the levels of C3 fragments bound to the injected autologous erythrocytes. This is the first report of defective complement receptor function in ulcerative colitis and alcoholic cirrhosis. Immunoglobulin G-dependent elimination of erythrocytes was confirmed to be lowered in all patient groups. The results suggest severe macrophage functional aberrations involving both complement receptors and Fc receptors as the basis of phagocytic defects in autoimmune/inflammatory conditions. In contrast, a general loss of macrophages might cause the functional loss in alcoholic cirrhosis.
Assuntos
Colite Ulcerativa/imunologia , Complemento C3b/imunologia , Eritrócitos/imunologia , Cirrose Hepática Alcoólica/imunologia , Cirrose Hepática Biliar/imunologia , Adulto , Idoso , Doenças Autoimunes/imunologia , Transfusão de Sangue Autóloga , Transfusão de Eritrócitos , Feminino , Testes Hematológicos , Humanos , Imunoglobulina G/imunologia , Macrófagos/imunologia , Masculino , Pessoa de Meia-Idade , Receptores de Complemento/imunologia , Receptores Fc/imunologiaRESUMO
Initially liver morphology of chronic destructive non-suppurative cholangitis (CDNC) is rather atypical. Therefore, early morphological diagnosis is difficult. First symptoms are severe pruritus and an increase of IgM, AP and gamma-GT. Own investigation of 101 CDNC patients showed that antimitochondrial antibodies (AMA) are generally later present than the increase of the a/m enzymes. Also remarkable is the fact that among 101 patients are 13 men generally observed during the last 3 years. The most difficult problem is the treatment of CDNC. Here we have to differentiate between symptomatic basic treatment and so-called specific treatment. As basic treatment, ammonia-reducing amino acids, phenobarbital and finally cholestyramine are administered in order to diminish the severe pruritus. The diet must be rich on pectine. Lactulose and bifidum milk improve the diminished detoxication function of the liver. As specific treatment prednisolone and/or azathioprin have disappointed. D-penicillamine can influence CDNC at least temporarily. Because of the frequent side-effects D-penicillamine should be administered only in low doses (100-200 mg daily together with 300 mg vitaminee B6). Until not it is uncertain if the extremely bad prognosis of CDNC can be improved by medical treatment of its early stages.